Drug Profile


Alternative Names: RDC5

Latest Information Update: 11 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chronos Therapeutics
  • Class Neuroprotectants; Osteoporosis therapies
  • Mechanism of Action Autophagy stimulants; Reactive oxygen species modulators; Synuclein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders; Obesity

Highest Development Phases

  • Phase I Neurodegenerative disorders
  • Preclinical Obesity
  • Discontinued Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 11 May 2016 RDC 5 is available for licensing as of 11 May 2016. http://chronostherapeutics.com/
  • 11 May 2016 Discontinued - Phase-I for Osteoporosis in United Kingdom (PO)
  • 11 May 2016 Discontinued - Preclinical for Postmenopausal osteoporosis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top